LASSBio-1359 is an adenosine receptor agonist. It acts by inducing relaxation of the corpus cavernosum. It also acts as a novel selective phosphodiesterase.
LASSBio-1632 is a novel anti-asthmatic lead candidate that selectively inhibits PDE4A and PDE4D isoenzymes, leading to the suppression of airway hyper-reactivity (AHR) and TNF-α production in lung tissue. With high experimental BBB permeability, LASSBio-1632 (7j) efficiently crosses the blood-brain barrier through passive diffusion [1].